Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | DT-9081 |
Synonyms | |
Therapy Description |
DT-9081 is an antagonist to EP4, which potentially relieves immunosuppression and may have anti-tumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DT-9081 | DT 9081|DT 9081 | DT-9081 is an antagonist to EP4, which potentially relieves immunosuppression and may have anti-tumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05582850 | Phase I | DT-9081 | DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours (EPRAD) | Recruiting | FRA | BEL | 0 |